Table 2.
Polled analysis of patient characteristics among included trials.
| Outcome | No. of Studies | Events/Participants or Mean ± SD |
Events | Heterogeneity between Trials |
p-Value for Differences across Groups |
|||
|---|---|---|---|---|---|---|---|---|
| Robotic | Laparoscopic | OR or MD |
95%CI | p-Value | I2 Statistic |
|||
| Sex, male | 39 | 2564/3858 (66.5%) |
3345/5408 (61.9%) |
1.16 | 1.05 to 1.28 | 0.32 | 9% | 0.003 |
| Age | 37 | 60.0 ± 16.1 | 62.2 ± 12.7 | −0.91 | −1.79 to 0.02 | <0.001 | 70% | 0.04 |
| BMI | 31 | 25.1 ± 4.9 | 24.6 ± 4.3 | 0.14 | −0.22 to 0.49 | <0.001 | 78% | 0.45 |
| ASA score | ||||||||
| 1 class | 27 | 603/2358 (25.6%) |
884/3628 (24.4%) |
0.97 | 0.84 to 1.12 | 0.45 | 0% | 0.70 |
| 2 class | 27 | 1333/2358 (56.5%) |
1878/3628 (51.8%) |
1.19 | 0.99 to 1.44 | 0.001 | 51% | 0.07 |
| 3 class | 27 | 385/2358 (16.3%) |
735/3628 (20.3%) |
0.84 | 0.68 to 1.04 | 0.08 | 30% | 0.11 |
| 4 class | 27 | 13/2358 (1.6%) |
36/3628 (3.5%) |
0.90 | 0.44 to 1.83 | 0.83 | 0% | 0.77 |
| Neoadjuvant therapy | 21 | 1000/2046 (48.9%) |
1347/3541 (38.0%) |
1.67 | 1.34 to 2.09 | 0.001 | 55% | <0.001 |
| Tumour distance from AV (cm) | 18 | 7.4 ± 3.5 | 8.5 ± 3.4 | −0.72 | −1.17 to −0.26 | <0.001 | 79% | 0.002 |
| Tumour location | ||||||||
| Upper rectum | 10 | 203/1385 (14.7%) |
476/2867 (16.6%) |
0.61 | 0.44 to 0.83 | 0.02 | 56% | 0.002 |
| Middle | 10 | 631/1385 (45.6%) |
1254/2867 (43.7%) |
1.11 | 0.93 to 1.32 | 0.21 | 25% | 0.24 |
| Lower | 14 | 800/1919 (41.7%) |
1334/3457 (38.6%) |
1.18 | 0.92 to 1.52 | <0.001 | 71% | 0.18 |
Legend: BMI = Body Mass index; CI: confidence interval; MD = mean difference; OR = odds ratio; SD = standard deviation. Note: Not all outcomes were reported in every study. “No. of studies” refers to the studies included in the analysis for the particular outcome.